NASDAQ:ANIP - ANI Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $52.93 +0.94 (+1.81 %) (As of 11/18/2018 02:29 PM ET)Previous Close$52.93Today's Range$51.0050 - $53.2452-Week Range$48.40 - $74.70Volume98,052 shsAverage Volume73,937 shsMarket Capitalization$627.54 millionP/E Ratio12.00Dividend YieldN/ABeta2.64 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. Receive ANIP News and Ratings via Email Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A Webwww.anipharmaceuticals.com Phone218-634-3500 Debt Debt-to-Equity Ratio1.04 Current Ratio3.34 Quick Ratio2.49 Price-To-Earnings Trailing P/E Ratio12.00 Forward P/E Ratio11.66 P/E GrowthN/A Sales & Book Value Annual Sales$176.84 million Price / Sales3.55 Cash Flow$5.9808 per share Price / Cash8.85 Book Value$16.23 per share Price / Book3.26 Profitability EPS (Most Recent Fiscal Year)$3.61 Net Income$-1,070,000.00 Net Margins0.23% Return on Equity28.39% Return on Assets12.27% Miscellaneous Employees173 Outstanding Shares11,860,000Market Cap$627.54 million OptionableOptionable ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions What is ANI Pharmaceuticals' stock symbol? ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP." How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals Inc (NASDAQ:ANIP) announced its quarterly earnings data on Tuesday, November, 6th. The specialty pharmaceutical company reported $1.29 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.17 by $0.12. The specialty pharmaceutical company had revenue of $50.70 million for the quarter, compared to the consensus estimate of $50.97 million. ANI Pharmaceuticals had a return on equity of 28.39% and a net margin of 0.23%. ANI Pharmaceuticals's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.11 EPS. View ANI Pharmaceuticals' Earnings History. When is ANI Pharmaceuticals' next earnings date? ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for ANI Pharmaceuticals. What guidance has ANI Pharmaceuticals issued on next quarter's earnings? ANI Pharmaceuticals issued an update on its FY18 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $4.80-5.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.91. The company issued revenue guidance of $195-205 million, compared to the consensus revenue estimate of $200.03 million. What price target have analysts set for ANIP? 2 brokerages have issued 1-year target prices for ANI Pharmaceuticals' stock. Their predictions range from $70.00 to $74.00. On average, they expect ANI Pharmaceuticals' stock price to reach $72.00 in the next year. This suggests a possible upside of 36.0% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals. What is the consensus analysts' recommendation for ANI Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals. Has ANI Pharmaceuticals been receiving favorable news coverage? Media stories about ANIP stock have been trending very positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ANI Pharmaceuticals earned a media sentiment score of 3.4 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days. Who are some of ANI Pharmaceuticals' key competitors? Some companies that are related to ANI Pharmaceuticals include Ascendis Pharma A/S (ASND), Allakos (ALLK), Blueprint Medicines (BPMC), Myokardia (MYOK), ACADIA Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Xencor (XNCR), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), Prestige Consumer Healthcare (PBH), Endocyte (ECYT) and TESARO (TSRO). Who are ANI Pharmaceuticals' key executives? ANI Pharmaceuticals' management team includes the folowing people: Mr. Arthur S. Przybyl, CEO, Pres & Director (Age 61)Mr. Stephen P. Carey, CFO & VP of Fin. (Age 47)Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 55)Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 46)Dr. David J. Sullivan, VP of Quality Operations Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.72%), Dimensional Fund Advisors LP (4.33%), LSV Asset Management (2.49%), First Manhattan Co. (1.82%), Renaissance Technologies LLC (1.51%) and Phocas Financial Corp. (0.82%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals. Which institutional investors are selling ANI Pharmaceuticals stock? ANIP stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Rice Hall James & Associates LLC, LSV Asset Management, BlackRock Inc., BlueMountain Capital Management LLC, SG Americas Securities LLC, Algert Global LLC and Credit Suisse AG. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Insider Buying and Selling for ANI Pharmaceuticals. Which institutional investors are buying ANI Pharmaceuticals stock? ANIP stock was bought by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, First Manhattan Co., Phocas Financial Corp., Dimensional Fund Advisors LP, Triarii Capital Management LP, Investment Counselors of Maryland LLC, Panagora Asset Management Inc. and Hussman Strategic Advisors Inc.. View Insider Buying and Selling for ANI Pharmaceuticals. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ANI Pharmaceuticals' stock price today? One share of ANIP stock can currently be purchased for approximately $52.93. How big of a company is ANI Pharmaceuticals? ANI Pharmaceuticals has a market capitalization of $627.54 million and generates $176.84 million in revenue each year. The specialty pharmaceutical company earns $-1,070,000.00 in net income (profit) each year or $3.61 on an earnings per share basis. ANI Pharmaceuticals employs 173 workers across the globe. What is ANI Pharmaceuticals' official website? The official website for ANI Pharmaceuticals is http://www.anipharmaceuticals.com. How can I contact ANI Pharmaceuticals? ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected] MarketBeat Community Rating for ANI Pharmaceuticals (NASDAQ ANIP)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 299 (Vote Outperform)Underperform Votes: 244 (Vote Underperform)Total Votes: 543MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/18/2018 by MarketBeat.com StaffFeatured Article: How can investors find ex-dividend dates?